Small-Cap Investor Forum

[MissionIR]

OncoSec Medical, Inc. (ONCS) Increasing Market Share through Development of Game-Changing ImmunoPulse™ Technology

OncoSec Medical, through the continued clinical development of its proprietary ImmunoPulse™ intratumoral cancer immunotherapy, is preparing to revolutionize the cancer treatment market. The company’s innovative therapeutic delivery system is designed to enhance local delivery and reception of DNA-based therapeutics through the use of electroporation, or electrical stimulation, meant to increase the permeability of the cell membrane. By supplying a sequence of short-duration electrical pulses to a tumor, ImmunoPulse has been shown effective in dramatically improving the uptake of DNA-based agents, thereby increasing the effectiveness of treatment options for various types of cancers by educating immune cells to recognize the disease.

To date, the company has primarily studied the benefits of its ImmunoPulse technology in combination with its DNA-based IL-12, a naturally occurring protein with immune-stimulating functions. OncoSec’s clinical pipeline currently includes phase II clinical studies of IL-12 for the treatment of metastatic melanoma, head and neck cancer and triple negative breast cancer. In early tests, the company has recorded promising results. In its multi-center phase II trial of IL-12 as a treatment for metastatic melanoma, half of all patients showed complete regression in at least one untreated lesion, demonstrating the immune-stimulating functions of the therapeutic. For OncoSec and its ImmunoPulse delivery system, these results could be just the beginning.

“While we work to advance our clinical studies, we are also continuing to explore the broader applications of our ImmunoPulse technology,” Punit Dhillon, president and chief executive officer of OncoSec, stated in a news release. “While our engineers work to develop advanced devices capable of accessing difficult-to-reach tumors, the discovery research team is investigating new DNA constructs and targets focused on defeating cancer’s ability to evade the immune system, allowing the patient’s immune system to recognize and attack the tumor.”

For prospective shareholders, the vast market potential of OncoSec’s therapeutic delivery system makes the company an intriguing investment opportunity moving forward. As of April 30, the company reported $25.4 million in cash and cash equivalents, which it expects will adequately fund operations for the next year. Additionally, the company’s uplisting to the NASDAQ Capital Market, which it completed in May, should provide a platform for increased visibility when the need for additional funding arises. With financial flexibility in place, OncoSec is in a strong position to make continued progress toward the eventual commercialization of its groundbreaking therapeutic pipeline in the coming months.

For more information, visit www.oncosec.com